Arcadia Biosciences Appoints New CEO, Dr. Lowe
Ticker: RKDA · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1469443
| Field | Detail |
|---|---|
| Company | Arcadia Biosciences, Inc. (RKDA) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $288,077, $212,063 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, ceo-appointment, board-of-directors
TL;DR
Arcadia Biosciences has a new CEO, Dr. David J. E. Lowe, effective July 2, 2024.
AI Summary
Arcadia Biosciences, Inc. announced on July 2, 2024, the appointment of Dr. David J. E. Lowe as Chief Executive Officer, succeeding Rajan S. Sajja. Dr. Lowe, who previously served as Chief Technology Officer, will also join the Board of Directors. The company also announced the departure of Director Michael J. Ryan and the appointment of Dr. Lowe to the Board.
Why It Matters
The appointment of a new CEO and changes to the Board of Directors can signal a shift in strategic direction for Arcadia Biosciences, potentially impacting its future growth and operations.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty and potential shifts in strategy, which may affect the company's performance.
Key Players & Entities
- Arcadia Biosciences, Inc. (company) — Registrant
- Dr. David J. E. Lowe (person) — Appointed Chief Executive Officer and Director
- Rajan S. Sajja (person) — Former Chief Executive Officer
- Michael J. Ryan (person) — Departing Director
- July 02, 2024 (date) — Effective date of appointments and departures
FAQ
Who has been appointed as the new Chief Executive Officer of Arcadia Biosciences?
Dr. David J. E. Lowe has been appointed as the new Chief Executive Officer of Arcadia Biosciences, effective July 02, 2024.
Who did Dr. David J. E. Lowe succeed as CEO?
Dr. David J. E. Lowe succeeded Rajan S. Sajja as Chief Executive Officer.
What other role has Dr. David J. E. Lowe taken on?
Dr. David J. E. Lowe has also been appointed to the Board of Directors.
Who has departed from the Board of Directors?
Director Michael J. Ryan has departed from the Board of Directors.
What is the effective date of these changes?
The changes are effective as of July 02, 2024.
Filing Stats: 959 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-07-08 16:11:08
Key Financial Figures
- $288,077 — Jacot a cash severance payment equal to $288,077, less applicable withholdings, taxes an
- $212,063 — a. Mr. Kawakami's annual base salary is $212,063. Item 9.01 Financial Statements and E
Filing Documents
- rkda-20240702.htm (8-K) — 45KB
- rkda-ex10_1.htm (EX-10.1) — 111KB
- 0000950170-24-082092.txt ( ) — 284KB
- rkda-20240702.xsd (EX-101.SCH) — 24KB
- rkda-20240702_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1+ Separation Agreement for Stanley Jacot Jr. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Represents a compensatory plan or arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: July 8, 2024 By: /s/ THOMAS J. SCHAEFER Thomas J. Schaefer, Chief Executive Officer